Lung Cancer Edition: Top Headlines for Week of July 15, 2024
Manage episode 429529148 series 3560281
In this edition, atezolizumab benefits PD-L1-selected patients with NSCLC, risks persist with e-cigarette use after quitting tobacco smoking and more. Read the full coverage here:
Adjuvant atezolizumab benefits PD-L1-selected patients with NSCLC
Lung cancer risks persist with e-cigarette use after quitting tobacco smoking
COPD, IPF end of life health care use differs from lung cancer
Tecentriq combination fails to improve survival in metastatic lung cancer
Risk for lung cancer reoccurrence may be associated with OSA-related hypoxemia
References:
Figueroa Rodriguez F, et al. 0468: CRASH: Cancer reoccurrence is accelerated by episodic hypoxemia. Presented at: SLEEP; June 1-5, 2024; Houston.
Kim Y, et al. Association of electronic cigarette use after conventional smoking cessation with lung cancer risk: A nationwide cohort study. Presented at: American Thoracic Society International Conference; May 18-22, 2024; San Diego.
Wakelee HA, et al. Abstract LBA8035. Presented at: ASCO Annual Meeting; May 31-June 4, 2024; Chicago.
118 episode